Table 5.

Phase II trials of radiolabelled anti-CD20 monoclonal antibodies in patients with follicular lymphoma that was considered “refractory” to rituximab (no objective response or response of less than 6 months duration following rituximab) [41] or had progressed after rituximab therapy [42]

	I-131 tositumomab	Y-90 ibritumomab tiuxetan
Number of patients	40	54
Median age of patients, years	57	54
Median number prior therapies	4	4
≥High-intermediate IPI score, %	21	19
Rituximab “refractory”, %	88	100
Percent with a tumour ≥5 cm, %	50	74
Percent with a tumour ≥7 cm, %	32	44
Bone marrow involved, %	32	32
Response rate, %	65	74
Median progression-free survival, months	10.4	6.8
Complete response rate, %	38	16

IPI, international prognostic index; LDH, lactate dehydrogenase